Yi Gu

发表

Preclinical pharmacokinetics, disposition, and translational pharmacokinetic/pharmacodynamic modeling of savolitinib, a novel selective cMet inhibitor.

Weiguo Qing, Hong-Can Ren, Y. Sai, 2019, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Contribution of machine learning to tumor growth inhibition modeling for hepatocellular carcinoma patients under Roblitinib (FGF401) drug treatment

D. Demanse, C. Meille, A. Jullion, 2022, CPT: pharmacometrics & systems pharmacology.

A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors

M. Kudo, J. Bruix, A. Zhu, 2022, Journal of experimental & clinical cancer research : CR.

ARX788, a Site-specific Anti-HER2 Antibody–Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1–resistant Breast and Gastric Cancers

S. Sakamuri, Feng Tian, S. Biroc, 2020, Molecular Cancer Therapeutics.

Nonclinical Development of Next-generation Site-specific HER2-targeting Antibody–drug Conjugate (ARX788) for Breast Cancer Treatment

Feng Tian, Yi Gu, Yanping Ji, 2020, Molecular Cancer Therapeutics.

Abstract CT106: Ph I/II study of FGF401 in adult pts with HCC or solid tumors characterized by FGFR4/KLB expression

A. Zhu, S. Choo, M. Schuler, 2017 .

Integration of Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy into Model‐Informed Dose Selection in Oncology First‐in‐Human Study: A Case of Roblitinib (FGF401)

D. Demanse, C. Meille, A. Jullion, 2022, Clinical pharmacology and therapeutics.

Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055).

Barry R Davies, Yi-long Wu, S. Runswick, 2012, Cancer research.

Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancer.

Weiguo Qing, Y. Sai, Yumin Cui, 2014, Journal of medicinal chemistry.

Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy

Weiguo Qing, Meifang Zhang, Y. Sai, 2014, Cancer biology & therapy.

A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors

M. Kudo, J. Bruix, A. Zhu, 2022, Journal of Experimental & Clinical Cancer Research.

cMet: Results in papillary renal cell carcinoma of a phase I study of AZD6094/volitinib leading to a phase 2 clinical trial with AZD6094/volitinib in patients with advanced papillary renal cell cancer (PRCC).

T. Choueiri, H. Burris, M. Millward, 2015 .

A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma

T. Yau, S. Choo, Jianming Xu, 2019, Therapeutic advances in medical oncology.

First-in-human phase I study of a selective c-Met inhibitor volitinib (HMP504/AZD6094) in patients with advanced solid tumors.

M. Millward, H. Gan, M. Frigault, 2014 .

Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor Fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics

Lixia Guo, Hong-Can Ren, Y. Sai, 2014, Cancer Chemotherapy and Pharmacology.